Title of cohort

    PAQUID

    Acronym for cohort

    PAQUID

    Name of Principal Investigator - Title

    Prof

    Name of Principal Investigator - First name

    Jean-François

    Name of Principal Investigator - Last name

    DARTIGUES

    Address of institution -Institution

    ISPED / INSERM U1219 / Université de Bordeaux

    Address of institution - Street address

    146 rue Léo Saignat

    Address of institution - City

    BORDEAUX

    Address of institution - Postcode

    33076

    Country

    France

    Website

    Funding source

    IPSEN France, Novartis Pharma France, CNSA (Caisse Nationale de Solidarité et d’Autonomie), Roche

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Alzheimer's disease and other dementias| Parkinson's disease

    Q1b. When are studies on the above condition(s) expected to become possible?

    Already possible

    Q2a. In a single sentence what is the stated aim of the cohort?

    To study cerebral and functional ageing

    Q2b. What distinguishes this cohort from other population cohorts?

    Population-based cohort

    Q3a. i) Number of publications that involve use of your cohort to date

    150

    Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    https://www.ncbi.nlm.nih.gov/pubmed/?term=PAQUID

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    65

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    until death

    Q4b. Study criteria: what are the inclusion criteria?

    65 or more years old subjects, living at home and randomly selected from the electoral rolls in 75 different sites of two French administrative districts

    Q4c. Study criteria: what are the exclusion criteria?

    Living in an institution

    Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

    1,000-5,000 participants

    Q6a. Please describe what measures are used to characterise participants

    Sociodemographic characteristics, lifestyle, medical antecedents, medications, depressive symptomatology and activity limitations were assessed at baseline and each follow-up time. A complete cognitive evaluation with systematic screening for dementia was performed at baseline and each follow-up time.

    Q6b. Are there additional measures for participants with a clinical disorder?

    Examination by a neurologist or a geriatrician

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    Yes

    If yes please specify

    Primary endpoint: dementia; secondary endpoint: functional evaluation

    Q7. What is the study design (select all that apply)?

    Prospective cohort| Longitudinal

    Q8. Are your cases matched by

    Q9a. Does your study include a specialised subset of control participants?

    Yes

    Q9b. If your study includes a specialised subset of control participants please describe

    Participants free of the disease can be used as controls

    Q10a. i) Please enter the data collection start date

    01/01/1988

    Q10a. ii) Please enter the data collection end date

    Last follow-up: 2016; however a next follow-up is planned

    Q10a. iii) Is data collection for this study

    Data collection ongoing| Data analysis ongoing| Closed to new patients

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Yes - intend to apply for funding

    Q11. Is data collected

    Only through the study

    Other please specify here

    Mainly through the study + link with cancer registry

    Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

    Yes (participants given permission to be re-contacted via PIs)

    Q13a. Please give information on the format and availability of data stored in a database (1)

    Data summarised in database

    % available

    100

    Q13a. Please give information on the format and availability of data stored in a database (2)

    No

    % available

    Q13a. Please give information on the format and availability of data stored in a database (3)

    No

    % available

    Q13a. Please give information on the format and availability of data stored in a database (4)

    No

    % available

    Other (please specify)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (1)

    Data is held as individual records

    % available

    100

    Q13b. Please give information on the format and availability of data held as individual records (2)

    No

    % available

    Q13b. Please give information on the format and availability of data held as individual records (3)

    Data held on computer based records

    % available

    100

    Q13b. Please give information on the format and availability of data held as individual records (4)

    No

    % available

    Please specify language used

    French

    Q14a. Is data available to other groups?

    Yes

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Apply to PI or co-ordinator at resource| Access independent of collaboration with PI

    Q15. What data sharing policy is specified as a condition of use?

    No policy exists

    Q16a. Are tissues/samples/DNA available to other groups?

    No

    Q16b i) If yes, please describe below:

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Q17. Is information on biological characteristics available to other groups?

    No

    Number of Patients

    % of total cohort

Types: Population Cohorts
Member States: France
Diseases: Alzheimer's disease & other dementias, Parkinson's disease & PD-related disorders
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF